Harmony Biosciences Holdings, Inc.
HRMYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Harmony Biosciences Holdings, Inc. (HRMY) is listed under Biotechnology. At a $2.10B market cap, Harmony Biosciences Holdings, Inc. ranks as a mid-cap company within healthcare. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Market Cap
$2.10B
Beta
1.01
P/E (TTM)
11.65
P/E (Fwd)
5.16
EPS (TTM)
$3.10
EPS (Fwd)
$7.00
ROE
20.5%
ROA
11.6%
Cash
$667.8M
Total Debt
$160.2M
Free CF
$182.8M
52W Change
20.0%
Annual Financials
Cash vs Debt
Where HRMY stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, HRMY finished 8.10% above its 150-day moving average ($34.70) and 8.22% above its 200-day moving average ($34.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HRMY overbought or oversold?
At the October 15, 2026 close, HRMY's RSI(14) was 27.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Harmony Biosciences Holdings, Inc. holds $667.8M in cash against $160.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $182.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 20.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $437.9M (2022) to $868.5M (2025), reflecting a 98% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing HRMY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.